ACH
PRQR icon

ArrowMark Colorado Holdings’s ProQR Therapeutics PRQR Stock Holding History

ArrowMark Colorado Holdings’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,164,722
Closed -$2.35M – 318
2025
Q4 		$2.35M Sell
1,164,722
-81,512
-7% -$190K 0.05% 235
2025
Q3 		$2.65M Buy
1,246,234
+46,596
+4% +$102K 0.05% 222
2025
Q2 		$2.45M Sell
1,199,638
-45,400
-4% -$73.8K 0.04% 221
2025
Q1 		$1.66M Buy
1,245,038
+63,625
+5% +$135K 0.03% 235
2024
Q4 		$3.13M Buy
+1,181,413
New +$3.75M 0.04% 221

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

ArrowMark Colorado Holdings's PRQR Position: Q1 2026 in Review

ArrowMark Colorado Holdings sold out of ProQR Therapeutics (PRQR) in Q1 2026, closing a stake of 1,164,722 shares — an estimated $2.35M sold.

ArrowMark Colorado Holdings first reported a position in PRQR in Q4 2024 and held it in 5 quarters. The position peaked at $3.13M in Q4 2024. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • ArrowMark Colorado Holdings reported no remaining ProQR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 1,164,722 ProQR Therapeutics shares in Q1 2026, an estimated $2.35M.
  • ArrowMark Colorado Holdings first reported a position in ProQR Therapeutics in Q4 2024 and held it in 5 quarters.
  • ArrowMark Colorado Holdings's ProQR Therapeutics position peaked at $3.13M in Q4 2024.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2026, filed 15 May 2026.